Although previous findings of CSPG4 IgE administration in a fully immunocompetent rat model may indicate lack of on-target off-tumor toxicity against minimally CSPG4-expressing normal tissues, the safety of CSPG4 IgE requires further investigation. Here, CSPG4 is linked to neoplasm.